Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2015)
20 slides from Csl's shareholder meeting presentation, Oct 15, 2015
Slide 1: CSL Limited Annual General Meeting
CSL Limited Annual General Meeting 15 October 2015
Slide 2: Legal Notice
Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all o
Slide 3: Reported Financials
Reported Financials Sales US$5,459 million, up 2% (up 7% @CC1) EBIT US$1,758 million, up 7% (up 10% @CC) • Adjusted for acquisition costs2 up 12% @CC NPAT US$1,379 million, up 6% (up 8% @CC) • Adjusted for acquisition costs up 10% @CC R&D investment US$463 million EPS US$2.92, up 8% (up 11% @CC) • A
Slide 4: Highlights
Highlights • Acquisition of Novartis global influenza vaccines business • bioCSL business turnaround • Hizentra® - EMA & U.S. FDA approve flexible dosing • CSL 654 (rIX-FP) – license application submitted in U.S. & EU • CSL 627 (rFVIII-SC) – license application submitted in U.S. • CSL 112 (rHDL) – g
Slide 5: Facilities Expansion: Investing for Growth
Facilities Expansion Investing for Growth Recombinant • Broke ground on rCOAG plant in Lengnau, Switzerland Plasma • Completed validation runs for the new Privigen® facility in BMW • Construction underway for new albumin facility in BMW • Obtained FDA and other regulatory approvals for the new base
Slide 6: Group Revenue FY15 US$5.6b
Group Revenue FY15 US$5.6b IPL 3% Product Pharma & Groupings Vaccines Specialty 8% Products 16% Other 8% IVIG 29% Peri-op 8% Albumin 14% SCIG 9% pd Coag rFVIII Hyper 10% IG 3% 8% 6
Slide 7: Broad Sales Reach
Broad Sales Reach FY15 US$5.5b North America 41% bioCSL 8% Asia 10% Europe 28% ROW 13% 7
Slide 8: CSL Behring Product Sales up 7% @ CC
CSL Behring Product Sales up 7% @ CC US$M 6,000 US$4,926m US$5,029m 5,000 Specialty Products 4,000 3,000 Immunoglobulins 2,000 Albumin 1,000 pdCoag Helixate® 0 Jun 14 Sales for the 12 month period Jun 15 8
Slide 9: Immunoglobulins Sales up 5% @CC
Immunoglobulins Sales up 5% @CC US$M Highlights 2,500 US$2,320m US$2,326m Normal IG volume up 8% IVIG 2,000 • Europe • CIDP indication driving strong Privigen® demand 1,500 • North America IVIG • Competitive pressure • 340B utilisation 1,000 SCIG • Ongoing strong demand for Hizentra® in North Americ
Slide 10: Albumin Sales up 12% @ CC
Albumin Sales up 12% @ CC US$M 800 US$754m US$694m Highlights 700 China 600 Albumin • Ongoing strong demand 500 • Improving penetration into Tier 2 & Tier 3 cities 400 US 300 • Solid demand continues • Initiatives focusing on IDNs 200 and large hospitals 100 0 Jun 14 Jun 15 Sales for the 12 month pe
Slide 11: Haemophilia Sales up 3% @ CC
Haemophilia Sales up 3% @ CC US$M Highlights 1,200 US$1,064m PdFVIII US$1,026m 1,000 • Growth in Beriate® – Brazil, pdCoag Poland and Germany 800 • Solid performance from Haemate® /Humate® 600 • Ongoing transition to recombinant therapies 400 Helixate® Helixate® • Positive results with US 200 patien
Slide 12: Specialty Products Sales up 15% @CC
Specialty Products Sales up 15% @CC US$M 1,000 Highlights US$923m 900 US$848m Kcentra® 800 Other • Ongoing strong demand in the Specialty U.S. 700 Products Berinert® P 600 • Self administration label driving 500 new patient take-up. 400 Zemaira® 300 Peri- • New patient acquisition Operative • Launch
Slide 13: bioCSL Sales up 11% @CC
bioCSL Sales up 11% @CC A$M1 Highlights 600 Business turnaround initiatives A$480m driving a return to growth 500 A$433m Influenza sales A$145m Pharma • Up 18% @CC 400 & vaccines • Increased U.S. sales following the re-establishment of in-house 300 commercial operations • First to market in U.S., U.
Slide 14: R&D Update
R&D Update rIX-FP • rIX-FP Phase III efficacy data supports 7-14 day dosing • BLA accepted for review by FDA in February • MAA review procedure commenced by EMA in March rVIII-SingleChain • Phase I/III data supports twice weekly dosing • BLA accepted for review by FDA in July rVIIa-FP • Congenital d
Slide 15: R&D Update
R&D Update Beriplex® • Commencement of Beriplex® Japan Phase III study Berinert® • Pivotal Phase III subcutaneous prophylaxis study recruiting well Zemaira®/Respreeza® (Alpha1-Proteinase Inhibitor) • Patients with AATD treated with Respreeza® have lower annual rate of lung density decline • EMA CHMP
Slide 16: Seqirus
Seqirus™ • Acquisition of Novartis global influenza vaccines business (NVS-IV) completed 31 July 2015 • Seqirus™ becomes the second largest influenza vaccine company globally • Combined influenza vaccine sales expected to approach US$1 billion in 3 to 5 years • Manufacturing plants in US, UK, German
Slide 17: Outlook for FY16
Outlook1 for FY16 “CSL Guidance Reaffirmed” CSL2 NVS-IV3 (11 Months) Revenue growth ~7% @CC4 Revenue ~US$450m5 NPAT growth ~5% @CC4 NPAT ~Breakeven • New share buyback A$1 billion6 • NVS-IV gain on acquisition • EPS growth will exceed NPAT less integration costs growth driven by past and ~US$130 mil
Slide 18: Business Growth
Business Growth Biotech mAbs in core therapeutic segments CSL112 New treatment paradigm in ACS High margin contributor Recombinant Coagulation Factors rIX-FP, rVIII-SC, rVIIa-FP, rVWF Specialty Products Multiple high margin contributors: RiaSTAP ®, Kcentra ® , CytoGam®, Berinert®, Zemaira® Core Prod
Slide 19: Financial Appendix
Financial Appendix1 CSL2 NVS-IV3 (11 months) Full Year ended June FY15 FY16 FY16 US$ Millions Actual Guidance Guidance Total Revenue 5,613 ~7% @CC4 ~4505 Reported Net Profit after Tax 1,379 ~Breakeven NVS-IV gain on acquisition less 22 ~(130) integration costs6 Adjusted Net Profit after Tax 1,401 ~5
Slide 20: CSL Limited Annual General Meeting
CSL Limited Annual General Meeting 15 October 2015 Contact - Mark Dehring Head of Investor Relations Telephone: +613 9389 3407 Email: [email protected]